Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Vytrus Biotech S.A. is a biotechnology company specializing in the development, production, and marketing of high-value natural active ingredients for the dermocosmetic and healthcare markets. It leverages proprietary plant stem cell technology to create sustainable, effective ingredients that promote skin health, hair care, and microbiota balance, such as Baolift™, Photobiome™, and Capilia Longa™. These premium actives, derived from innovative biotechnological processes, offer superior efficacy compared to traditional plant extracts while saving over 99% in arable soil and water resources. Vytrus Biotech S.A. emphasizes environmental sustainability, ethical sourcing, and certifications like GMP and EcoVadis Platinum Medal, ensuring controlled production with minimal ecological impact. The company serves global cosmetics brands across five continents through an extensive distributor network, focusing on sectors like skincare, haircare, and deodorants. Founded in 2009 and headquartered in Terrassa, Barcelona, Spain, Vytrus Biotech S.A. plays a key role in advancing natural, biotech-driven innovation in the cosmetics industry, meeting demand for clean beauty products.
€18.50
+€0.10 (+0.54%)
EOD Jun 23, 2026 · Twelve Data
Margins and capital returns are both well above average: 38.01% operating margin, ROIC at 26.75%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue up 66.0% YoY with margins expanding 18.1pp.
At 43x earnings, the current multiple leaves limited room for execution misses or growth deceleration.
43.0x earnings, 102.1x FCF. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€8M
▲ +66.0% YoY
Net Income (TTM)
€3M
▲ +183.7% YoY
Op. Margin
38.01%
▲ +18.1pp YoY
ROIC
26.75%
▲ +15.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€1M
▲ +90.7% YoY
Op. Cash Flow (TTM)
€2M
▲ +147.2% YoY
Net Debt
-€1M
Net Cash Position
Cash & Equiv.
€3M
3Y CAGR: +31.5%
Continue Research